-continued

```
180
                                 185
                                                     190
Ile Ala Arg Glu Arg Tyr Ala Lys Phe Lys Arg
       195
<210> SEQ ID NO 18
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: HPV16 E6 aa41-65
<400> SEQUENCE: 18
Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg Asp
Leu Cys Ile Val Tyr Arg Asp Gly Asn
<210> SEQ ID NO 19
<211> LENGTH: 35
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: HPV16 E7 aa43-77
<400> SEOUENCE: 19
Gly Gln Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe Cys
Cys Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val
                                25
Asp Ile Arg
        35
```

What is claimed is:

- 1. A composition for treating a subject having persistent HPV infection, the composition comprising:
 - a. a first vaccine composition comprising a recombinant adenovirus vector comprising a first nucleic acid sequence encoding a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the first nucleic acid sequence is operably linked to a first promoter, and
 - a second vaccine composition comprising a recombinant pox virus vector comprising a second nucleic acid sequence encoding a second polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the second nucleic acid sequence is operably linked to a second promoter;
 - wherein one of the first vaccine composition and the second vaccine composition is administered to the subject for priming vaccination and the other is administered to the subject for boosting administration.
- 2. The composition of claim 1, wherein the first vaccine composition is administered to the subject for priming vaccination and the second vaccine is administered to the subject for boosting administration.
- 3. The composition of claim 1, wherein the second vaccine composition is administered to the subject for priming vaccination and the first vaccine is administered to the subject for boosting administration.

- **4**. The composition of claim **1**, wherein the recombinant adenovirus vector of the first vaccine composition is a recombinant human adenovirus serotype 26 (Ad26) vector.
- 5. The composition of claim 1, wherein the recombinant pox virus vector is a Modified Vaccinia Ankara (MVA) vector.
- **6**. The composition of claim **1**, wherein the first and second polypeptides each independently further comprise a leader sequence.
- 7. The composition of claim 1, wherein the first and second polypeptides each independently further comprise at least one epitope of a human papillomavirus (HPV) E2 protein.
- **8**. The composition of claim 7, wherein the first and second polypeptides each independently comprise an HPV16 E2 protein having a deletion or mutation in the DNA binding domain of the HPV16 E2 protein.
- **9**. The composition of claim **8**, wherein the HPV16 E2 protein is fused to the N-terminus of the amino acid sequence of SEQ ID NO: 1.
- 10. The composition of claim 8, wherein the HPV16 E2 protein is fused to the C-terminus of the amino acid sequence of SEQ ID NO: 1.
- 11. The composition of claim 8, wherein the first and second polypeptides each independently comprise SEQ ID NO: 3 or SEQ ID NO: 5.